Longbio Pharma (Suzhou) Co (HKSE:01779) EV-to-FCF: (As of Aug. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01779 Longbio Pharma (Suzhou) Co Ltd HKSE:01779
10 GF Score
Price HK$113.00
View Full Analysis

What is Longbio Pharma (Suzhou) Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Longbio Pharma (Suzhou) Co's Enterprise Value is HK$8,446.36 Mil. Longbio Pharma (Suzhou) Co does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Longbio Pharma (Suzhou) Co's EV-to-FCF at this moment.

The historical rank and industry rank for Longbio Pharma (Suzhou) Co's EV-to-FCF or its related term are showing as below:

HKSE:01779' s EV-to-FCF Range Over the Past 10 Years
Min: -60.96   Med: 0   Max: 0
Current: -60.96
HKSE:01779's EV-to-FCF is ranked worse than
100% of 335 companies
in the Biotechnology industry
Industry Median: 17.55 vs HKSE:01779: -60.96

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-09), Longbio Pharma (Suzhou) Co's stock price is HK$113.00. Longbio Pharma (Suzhou) Co does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Longbio Pharma (Suzhou) Co's PE Ratio (TTM) at this moment.

Longbio Pharma (Suzhou) Co  (HKSE:01779) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Longbio Pharma (Suzhou) Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=113.00/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Longbio Pharma (Suzhou) Co EV-to-FCF Related Terms

Longbio Pharma (Suzhou) Co EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Longbio Pharma (Suzhou) Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longbio Pharma (Suzhou) Co EV-to-FCF Chart

Longbio Pharma (Suzhou) Co Annual Data
Trend Dec24 Dec25
EV-to-FCF
0.00 0.00

Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24 Dec25
EV-to-FCF 0.00 0.00

HKSE:01779 vs VRTX, REGN, RVMD: EV-to-FCF Comparison

For the Biotechnology subindustry, Longbio Pharma (Suzhou) Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longbio Pharma (Suzhou) Co EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longbio Pharma (Suzhou) Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Longbio Pharma (Suzhou) Co's EV-to-FCF falls into.


HKSE:01779
10GF Score
Longbio Pharma (Suzhou) Co Ltd HKSE:01779
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longbio Pharma (Suzhou) Co EV-to-FCF Calculation

Longbio Pharma (Suzhou) Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=8446.357/
=

Longbio Pharma (Suzhou) Co Business Description

Address No. 128 Yinhe Road, Dongnan Subdistrict, 5th Floor, Building F, Area A, Changshu City, Jiangsu Province, Suzhou, CHN
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score

Get the complete analysis for HKSE:01779

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$113.00
Price